Prognostic Factors after Potentially Curative Resection in Stage II or III Colon Cancer

It is important to identify factors that are predictive of outcome after a curative resection in colon cancer in order to optimize adjuvant therapy. To investigate these prognostic factors we conducted a retrospective analysis of our clinicopathological data. A total of 190 patients with a pathologi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Kurume medical journal 2005, Vol.52(3), pp.67-71
Hauptverfasser: OGATA, YUTAKA, TORIGOE, SHOJIRO, MATONO, KEIKO, SASATOMI, TERUO, ISHIBASHI, NOBUYA, SHIDA, SEIICHIRO, OHKITA, AKIRA, MIZOBE, TOMOAKI, IKEDA, SATORU, OGOU, SHUJIRO, OZASA, HIROYUKI, SHIROUZU, KAZUO
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 71
container_issue 3
container_start_page 67
container_title Kurume medical journal
container_volume 52
creator OGATA, YUTAKA
TORIGOE, SHOJIRO
MATONO, KEIKO
SASATOMI, TERUO
ISHIBASHI, NOBUYA
SHIDA, SEIICHIRO
OHKITA, AKIRA
MIZOBE, TOMOAKI
IKEDA, SATORU
OGOU, SHUJIRO
OZASA, HIROYUKI
SHIROUZU, KAZUO
description It is important to identify factors that are predictive of outcome after a curative resection in colon cancer in order to optimize adjuvant therapy. To investigate these prognostic factors we conducted a retrospective analysis of our clinicopathological data. A total of 190 patients with a pathological stage II or III colon cancer underwent potentially curative resection with lymphadenectomy at our hospital between 1990 and 1998. These patients received no preoperative chemotherapy, immunotherapy or radiotherapy. Postoperative adjuvant chemotherapy using oral fluoropyrimidines was performed in 127 patients, and the other 63 patients underwent surgery alone. Univariate and multivariate analyses for prognostic factors were carried out. The univariate analysis revealed that invasion to adjacent organs, N1-2, positive mesenteric lymph node metastasis (MLN+), lymphatic permeation (ly) 1-3, venous invasion (v) 1-3, and v2-3 were each significant factors indicating worse disease-free survival, and that N1-2, MLN+, ly1-3, v1-3 and v2-3 were each significant factors for worse overall survival. In the multivariate analysis, MLN+ and v1-3 were significant factors for worse disease-free survival, and for worse overall survival. In conclusion, stage II or III colon cancer patients positive for mesenteric lymph node metastasis or for venous invasion have a greater risk of recurrence and death after potentially curative resection. Postoperative adjuvant chemotherapy using oral fluoropyrimidines did not significantly reduce the risk of recurrence and death in these patients. More effective adjuvant chemotherapy than oral fluoropyrimidine should be considered, especially in such high-risk patients.
doi_str_mv 10.2739/kurumemedj.52.67
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69070966</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69070966</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5077-368887ffb51b6d48bba5b2ae73fc1019a0821b943a5fd255ca1d26dffe15e90e3</originalsourceid><addsrcrecordid>eNpdkE1LAzEQhoMoWqt3T5KTt61JtvnYoyxVC4LFDzyGbHaiW7ebmmQF_70rLS14mYF5n3kPD0IXlEyYzIvrzz70K1hBvZxwNhHyAI2oUjRjpCCHaEQIyzMuZHGCTmNcEjJVipFjdELFlDEq6Qi9LYJ_73xMjcW3xiYfIjYuQcALn6BLjWnbH1z2waTmG_ATRLCp8R1uOvyczDvg-Rz7MMw5Ln07BKXpLIQzdORMG-F8u8fo9Xb2Ut5nD4938_LmIbOcSJnlQiklnas4rUQ9VVVleMUMyNxZSmhhiGK0Kqa54a5mnFtDayZq54ByKAjkY3S16V0H_9VDTHrVRAttazrwfdSiIJIUQgwg2YA2-BgDOL0OzcqEH02J_pOp9zI1Z1rI4eVy291Xw3n_sLU3ALMNsIx_KnaACYPOFv415psh5C63HyZo6PJfr0yM1g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69070966</pqid></control><display><type>article</type><title>Prognostic Factors after Potentially Curative Resection in Stage II or III Colon Cancer</title><source>J-STAGE Free</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>OGATA, YUTAKA ; TORIGOE, SHOJIRO ; MATONO, KEIKO ; SASATOMI, TERUO ; ISHIBASHI, NOBUYA ; SHIDA, SEIICHIRO ; OHKITA, AKIRA ; MIZOBE, TOMOAKI ; IKEDA, SATORU ; OGOU, SHUJIRO ; OZASA, HIROYUKI ; SHIROUZU, KAZUO</creator><creatorcontrib>OGATA, YUTAKA ; TORIGOE, SHOJIRO ; MATONO, KEIKO ; SASATOMI, TERUO ; ISHIBASHI, NOBUYA ; SHIDA, SEIICHIRO ; OHKITA, AKIRA ; MIZOBE, TOMOAKI ; IKEDA, SATORU ; OGOU, SHUJIRO ; OZASA, HIROYUKI ; SHIROUZU, KAZUO</creatorcontrib><description>It is important to identify factors that are predictive of outcome after a curative resection in colon cancer in order to optimize adjuvant therapy. To investigate these prognostic factors we conducted a retrospective analysis of our clinicopathological data. A total of 190 patients with a pathological stage II or III colon cancer underwent potentially curative resection with lymphadenectomy at our hospital between 1990 and 1998. These patients received no preoperative chemotherapy, immunotherapy or radiotherapy. Postoperative adjuvant chemotherapy using oral fluoropyrimidines was performed in 127 patients, and the other 63 patients underwent surgery alone. Univariate and multivariate analyses for prognostic factors were carried out. The univariate analysis revealed that invasion to adjacent organs, N1-2, positive mesenteric lymph node metastasis (MLN+), lymphatic permeation (ly) 1-3, venous invasion (v) 1-3, and v2-3 were each significant factors indicating worse disease-free survival, and that N1-2, MLN+, ly1-3, v1-3 and v2-3 were each significant factors for worse overall survival. In the multivariate analysis, MLN+ and v1-3 were significant factors for worse disease-free survival, and for worse overall survival. In conclusion, stage II or III colon cancer patients positive for mesenteric lymph node metastasis or for venous invasion have a greater risk of recurrence and death after potentially curative resection. Postoperative adjuvant chemotherapy using oral fluoropyrimidines did not significantly reduce the risk of recurrence and death in these patients. More effective adjuvant chemotherapy than oral fluoropyrimidine should be considered, especially in such high-risk patients.</description><identifier>ISSN: 0023-5679</identifier><identifier>EISSN: 1881-2090</identifier><identifier>DOI: 10.2739/kurumemedj.52.67</identifier><identifier>PMID: 16422171</identifier><language>eng</language><publisher>Japan: Kurume University School of Medicine</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; colon cancer ; Colonic Neoplasms - mortality ; Colonic Neoplasms - pathology ; Colonic Neoplasms - surgery ; Female ; Humans ; Lymphatic Metastasis ; Male ; metastasis to the mesenteric lymph node ; Middle Aged ; Neoplasm Staging ; oral fluoropyrimidine ; postoperative adjuvant chemotherapy ; Prognosis ; prognostic factor</subject><ispartof>The Kurume Medical Journal, 2005, Vol.52(3), pp.67-71</ispartof><rights>2005 Kurume University School of Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5077-368887ffb51b6d48bba5b2ae73fc1019a0821b943a5fd255ca1d26dffe15e90e3</citedby><cites>FETCH-LOGICAL-c5077-368887ffb51b6d48bba5b2ae73fc1019a0821b943a5fd255ca1d26dffe15e90e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16422171$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OGATA, YUTAKA</creatorcontrib><creatorcontrib>TORIGOE, SHOJIRO</creatorcontrib><creatorcontrib>MATONO, KEIKO</creatorcontrib><creatorcontrib>SASATOMI, TERUO</creatorcontrib><creatorcontrib>ISHIBASHI, NOBUYA</creatorcontrib><creatorcontrib>SHIDA, SEIICHIRO</creatorcontrib><creatorcontrib>OHKITA, AKIRA</creatorcontrib><creatorcontrib>MIZOBE, TOMOAKI</creatorcontrib><creatorcontrib>IKEDA, SATORU</creatorcontrib><creatorcontrib>OGOU, SHUJIRO</creatorcontrib><creatorcontrib>OZASA, HIROYUKI</creatorcontrib><creatorcontrib>SHIROUZU, KAZUO</creatorcontrib><title>Prognostic Factors after Potentially Curative Resection in Stage II or III Colon Cancer</title><title>Kurume medical journal</title><addtitle>Kurume Med. J.</addtitle><description>It is important to identify factors that are predictive of outcome after a curative resection in colon cancer in order to optimize adjuvant therapy. To investigate these prognostic factors we conducted a retrospective analysis of our clinicopathological data. A total of 190 patients with a pathological stage II or III colon cancer underwent potentially curative resection with lymphadenectomy at our hospital between 1990 and 1998. These patients received no preoperative chemotherapy, immunotherapy or radiotherapy. Postoperative adjuvant chemotherapy using oral fluoropyrimidines was performed in 127 patients, and the other 63 patients underwent surgery alone. Univariate and multivariate analyses for prognostic factors were carried out. The univariate analysis revealed that invasion to adjacent organs, N1-2, positive mesenteric lymph node metastasis (MLN+), lymphatic permeation (ly) 1-3, venous invasion (v) 1-3, and v2-3 were each significant factors indicating worse disease-free survival, and that N1-2, MLN+, ly1-3, v1-3 and v2-3 were each significant factors for worse overall survival. In the multivariate analysis, MLN+ and v1-3 were significant factors for worse disease-free survival, and for worse overall survival. In conclusion, stage II or III colon cancer patients positive for mesenteric lymph node metastasis or for venous invasion have a greater risk of recurrence and death after potentially curative resection. Postoperative adjuvant chemotherapy using oral fluoropyrimidines did not significantly reduce the risk of recurrence and death in these patients. More effective adjuvant chemotherapy than oral fluoropyrimidine should be considered, especially in such high-risk patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>colon cancer</subject><subject>Colonic Neoplasms - mortality</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colonic Neoplasms - surgery</subject><subject>Female</subject><subject>Humans</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>metastasis to the mesenteric lymph node</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>oral fluoropyrimidine</subject><subject>postoperative adjuvant chemotherapy</subject><subject>Prognosis</subject><subject>prognostic factor</subject><issn>0023-5679</issn><issn>1881-2090</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE1LAzEQhoMoWqt3T5KTt61JtvnYoyxVC4LFDzyGbHaiW7ebmmQF_70rLS14mYF5n3kPD0IXlEyYzIvrzz70K1hBvZxwNhHyAI2oUjRjpCCHaEQIyzMuZHGCTmNcEjJVipFjdELFlDEq6Qi9LYJ_73xMjcW3xiYfIjYuQcALn6BLjWnbH1z2waTmG_ATRLCp8R1uOvyczDvg-Rz7MMw5Ln07BKXpLIQzdORMG-F8u8fo9Xb2Ut5nD4938_LmIbOcSJnlQiklnas4rUQ9VVVleMUMyNxZSmhhiGK0Kqa54a5mnFtDayZq54ByKAjkY3S16V0H_9VDTHrVRAttazrwfdSiIJIUQgwg2YA2-BgDOL0OzcqEH02J_pOp9zI1Z1rI4eVy291Xw3n_sLU3ALMNsIx_KnaACYPOFv415psh5C63HyZo6PJfr0yM1g</recordid><startdate>2005</startdate><enddate>2005</enddate><creator>OGATA, YUTAKA</creator><creator>TORIGOE, SHOJIRO</creator><creator>MATONO, KEIKO</creator><creator>SASATOMI, TERUO</creator><creator>ISHIBASHI, NOBUYA</creator><creator>SHIDA, SEIICHIRO</creator><creator>OHKITA, AKIRA</creator><creator>MIZOBE, TOMOAKI</creator><creator>IKEDA, SATORU</creator><creator>OGOU, SHUJIRO</creator><creator>OZASA, HIROYUKI</creator><creator>SHIROUZU, KAZUO</creator><general>Kurume University School of Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2005</creationdate><title>Prognostic Factors after Potentially Curative Resection in Stage II or III Colon Cancer</title><author>OGATA, YUTAKA ; TORIGOE, SHOJIRO ; MATONO, KEIKO ; SASATOMI, TERUO ; ISHIBASHI, NOBUYA ; SHIDA, SEIICHIRO ; OHKITA, AKIRA ; MIZOBE, TOMOAKI ; IKEDA, SATORU ; OGOU, SHUJIRO ; OZASA, HIROYUKI ; SHIROUZU, KAZUO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5077-368887ffb51b6d48bba5b2ae73fc1019a0821b943a5fd255ca1d26dffe15e90e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>colon cancer</topic><topic>Colonic Neoplasms - mortality</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colonic Neoplasms - surgery</topic><topic>Female</topic><topic>Humans</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>metastasis to the mesenteric lymph node</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>oral fluoropyrimidine</topic><topic>postoperative adjuvant chemotherapy</topic><topic>Prognosis</topic><topic>prognostic factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OGATA, YUTAKA</creatorcontrib><creatorcontrib>TORIGOE, SHOJIRO</creatorcontrib><creatorcontrib>MATONO, KEIKO</creatorcontrib><creatorcontrib>SASATOMI, TERUO</creatorcontrib><creatorcontrib>ISHIBASHI, NOBUYA</creatorcontrib><creatorcontrib>SHIDA, SEIICHIRO</creatorcontrib><creatorcontrib>OHKITA, AKIRA</creatorcontrib><creatorcontrib>MIZOBE, TOMOAKI</creatorcontrib><creatorcontrib>IKEDA, SATORU</creatorcontrib><creatorcontrib>OGOU, SHUJIRO</creatorcontrib><creatorcontrib>OZASA, HIROYUKI</creatorcontrib><creatorcontrib>SHIROUZU, KAZUO</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Kurume medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OGATA, YUTAKA</au><au>TORIGOE, SHOJIRO</au><au>MATONO, KEIKO</au><au>SASATOMI, TERUO</au><au>ISHIBASHI, NOBUYA</au><au>SHIDA, SEIICHIRO</au><au>OHKITA, AKIRA</au><au>MIZOBE, TOMOAKI</au><au>IKEDA, SATORU</au><au>OGOU, SHUJIRO</au><au>OZASA, HIROYUKI</au><au>SHIROUZU, KAZUO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Factors after Potentially Curative Resection in Stage II or III Colon Cancer</atitle><jtitle>Kurume medical journal</jtitle><addtitle>Kurume Med. J.</addtitle><date>2005</date><risdate>2005</risdate><volume>52</volume><issue>3</issue><spage>67</spage><epage>71</epage><pages>67-71</pages><issn>0023-5679</issn><eissn>1881-2090</eissn><abstract>It is important to identify factors that are predictive of outcome after a curative resection in colon cancer in order to optimize adjuvant therapy. To investigate these prognostic factors we conducted a retrospective analysis of our clinicopathological data. A total of 190 patients with a pathological stage II or III colon cancer underwent potentially curative resection with lymphadenectomy at our hospital between 1990 and 1998. These patients received no preoperative chemotherapy, immunotherapy or radiotherapy. Postoperative adjuvant chemotherapy using oral fluoropyrimidines was performed in 127 patients, and the other 63 patients underwent surgery alone. Univariate and multivariate analyses for prognostic factors were carried out. The univariate analysis revealed that invasion to adjacent organs, N1-2, positive mesenteric lymph node metastasis (MLN+), lymphatic permeation (ly) 1-3, venous invasion (v) 1-3, and v2-3 were each significant factors indicating worse disease-free survival, and that N1-2, MLN+, ly1-3, v1-3 and v2-3 were each significant factors for worse overall survival. In the multivariate analysis, MLN+ and v1-3 were significant factors for worse disease-free survival, and for worse overall survival. In conclusion, stage II or III colon cancer patients positive for mesenteric lymph node metastasis or for venous invasion have a greater risk of recurrence and death after potentially curative resection. Postoperative adjuvant chemotherapy using oral fluoropyrimidines did not significantly reduce the risk of recurrence and death in these patients. More effective adjuvant chemotherapy than oral fluoropyrimidine should be considered, especially in such high-risk patients.</abstract><cop>Japan</cop><pub>Kurume University School of Medicine</pub><pmid>16422171</pmid><doi>10.2739/kurumemedj.52.67</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0023-5679
ispartof The Kurume Medical Journal, 2005, Vol.52(3), pp.67-71
issn 0023-5679
1881-2090
language eng
recordid cdi_proquest_miscellaneous_69070966
source J-STAGE Free; MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
colon cancer
Colonic Neoplasms - mortality
Colonic Neoplasms - pathology
Colonic Neoplasms - surgery
Female
Humans
Lymphatic Metastasis
Male
metastasis to the mesenteric lymph node
Middle Aged
Neoplasm Staging
oral fluoropyrimidine
postoperative adjuvant chemotherapy
Prognosis
prognostic factor
title Prognostic Factors after Potentially Curative Resection in Stage II or III Colon Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T22%3A02%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Factors%20after%20Potentially%20Curative%20Resection%20in%20Stage%20II%20or%20III%20Colon%20Cancer&rft.jtitle=Kurume%20medical%20journal&rft.au=OGATA,%20YUTAKA&rft.date=2005&rft.volume=52&rft.issue=3&rft.spage=67&rft.epage=71&rft.pages=67-71&rft.issn=0023-5679&rft.eissn=1881-2090&rft_id=info:doi/10.2739/kurumemedj.52.67&rft_dat=%3Cproquest_cross%3E69070966%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69070966&rft_id=info:pmid/16422171&rfr_iscdi=true